Sinovac Biotech Ltd SVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SVA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.00
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- $0.00
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 23.52
- Price/Sales
- 1.83
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 4,275
- Website
- http://www.sinovac.com
Comparables
Valuation
|
Metric
|
SVA
|
01099
|
06185
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.52 | 6.52 | — |
Price/Book Value | 1.82 | 0.79 | 0.74 |
Price/Sales | 1.83 | 0.10 | 11.31 |
Price/Cash Flow | 8.10 | — | — |
Price/Earnings
SVA
01099
06185
Financial Strength
|
Metric
|
SVA
|
01099
|
06185
|
|---|---|---|---|
Quick Ratio | 9.73 | 1.05 | 1.86 |
Current Ratio | 9.89 | 1.32 | 2.00 |
Interest Coverage | −1,215.78 | — | −31.41 |
Quick Ratio
SVA
01099
06185
Profitability
|
Metric
|
SVA
|
01099
|
06185
|
|---|---|---|---|
Return on Assets (Normalized) | −5.54% | — | −10.29% |
Return on Equity (Normalized) | −8.78% | — | −17.50% |
Return on Invested Capital (Normalized) | −6.80% | — | −12.58% |
Return on Assets
SVA
01099
06185
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zbkxqmnvw | Vmvtg | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pgmstfrz | Qqrxgnz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tbblslw | Tcjvnq | $99.5 Bil | |
MRNA
| Moderna Inc | Vqgnwtll | Tfn | $38.8 Bil | |
ARGX
| argenx SE ADR | Sxmmwkz | Lqcdr | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Zxknmzqqg | Dhm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fqzjrcynf | Smzdlng | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fxfjblzs | Rfwndm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sqptgjywv | Jmbqjd | $12.5 Bil | |
INCY
| Incyte Corp | Wfnydmq | Styfd | $11.6 Bil |